Overview

BR55 in Prostate Cancer: an Exploratory Clinical Trial

Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether BR55 is able to identify areas of VEGFR2 expression in human prostate by ultrasound molecular imaging. This will be compared with histopathology analysis (location based on expression of VEGFR2 in tissue specimens determined by immuno-histochemistry, IHC).
Phase:
Early Phase 1
Details
Lead Sponsor:
Bracco Diagnostics, Inc
Collaborator:
Bracco Imaging S.p.A.